- Full Year 2023 Faron Pharmaceuticals Oy Earnings Call TranscriptMar 13, 2024£1.2 (+7.41%)Earnings
- Faron Pharmaceuticals Oy at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Faron Pharmaceuticals Oy Recent BEXMAB results and future outlook Event TranscriptOct 11, 2023
- Half Year 2023 Faron Pharmaceuticals Oy Earnings Call TranscriptAug 29, 2023£2.49 (+11.11%)Earnings
- Faron Pharmaceuticals Oy at Canaccord Genuity Growth Conference TranscriptAug 10, 2023
- Faron Pharmaceuticals Oy BEXMAB Study Update TranscriptJul 19, 2023
- Full Year 2022 Faron Pharmaceuticals Oy Earnings Call TranscriptMar 02, 2023£2.74 (+1.54%)Earnings
- Half Year 2022 Faron Pharmaceuticals Oy Earnings Call TranscriptAug 25, 2022£1.52 (-5.19%)Earnings
- Full Year 2021 Faron Pharmaceuticals Oy Earnings Call TranscriptMar 25, 2022£1.95 (+0.43%)Earnings
- Half Year 2021 Faron Pharmaceuticals Oy Earnings Call TranscriptAug 26, 2021£3.82 (-5.15%)Earnings
Faron Pharmaceuticals Oy Recent BEXMAB results and future outlook Event Transcript
Good afternoon to all in Europe, and good morning for those on the other side of the pond. I'm Markku Jalkanen, Faron's CEO. I'm here today with our Director for Medical Affairs, Inka Pawlitzky. We are going to present you the recent update of the BEXMAB data. Very exciting one; I hope you really like it.
And then just a reminder, after the presentations, you have a chance to really make questions, and you can already do it during the presentation. Just connect to the link which was in the invite and send the questions in, and then they will be presented to us post the meeting.
So welcome again, and we will move on. I will show the mandatory disclaimer because we will be making forward-looking statements. As you know, the lead product we have is this bexmarilimab. It regulates the function of Clever-1 molecule, which is the major immunosuppressive elements on macrophages or monocytes or myeloid cells.
And by that matter, it can generate a significant suppressed immune environment to control the host defense system.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)